{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophagogastric+Adenocarcinoma",
    "query": {
      "condition": "Esophagogastric Adenocarcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophagogastric+Adenocarcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T09:24:24.407Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00004235",
      "title": "Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2000-01",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-06-11T09:24:24.407Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004235"
    },
    {
      "nct_id": "NCT02013154",
      "title": "A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophageal Neoplasms",
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Gastroesophageal Cancer",
        "Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "DKN-01 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "DKN-01 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leap Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2014-05-05",
      "completion_date": "2021-01-11",
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-06-11T09:24:24.407Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013154"
    },
    {
      "nct_id": "NCT00447330",
      "title": "Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Neoplasms",
        "Stomach Neoplasms",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2007-02",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2015-02-13",
      "last_synced_at": "2026-06-11T09:24:24.407Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00447330"
    },
    {
      "nct_id": "NCT02358863",
      "title": "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Modified FOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel/Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "IRI/EPI",
          "type": "DRUG"
        },
        {
          "name": "EPI/Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan/Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2015-02",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-06-11T09:24:24.407Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02358863"
    },
    {
      "nct_id": "NCT05544929",
      "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Cutaneous Melanoma",
        "Carcinoma, Renal Cell",
        "Carcinoma, Ovarian Epithelial",
        "Nasopharyngeal Carcinoma",
        "Carcinoma, Thymic",
        "Anal Cancer",
        "Mesothelioma",
        "Esophagogastric Cancer",
        "High Microsatellite Instability Colorectal Carcinoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "KFA115",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 126,
      "start_date": "2022-10-26",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-06-11T09:24:24.407Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05544929"
    },
    {
      "nct_id": "NCT01769508",
      "title": "Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2 Positive Esophagogastric Cancer"
      ],
      "interventions": [
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Lapatinib",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2013-02",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-06-13",
      "last_synced_at": "2026-06-11T09:24:24.407Z",
      "location_count": 9,
      "location_summary": "Fort Myers, Florida • Orlando, Florida • Pensacola, Florida + 6 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01769508"
    },
    {
      "nct_id": "NCT06623396",
      "title": "A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mesothelin Positive",
        "Mesothelin-Expressing Tumors",
        "Esophageal Adenocarcinoma",
        "Esophageal Adenocarcinomas",
        "Esophagogastric Adenocarcinoma",
        "Peritoneal Carcinomatosis",
        "Breast Neoplasms",
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "M28z1XXPD1DNR CAR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-09-30",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-06-11T09:24:24.407Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06623396"
    },
    {
      "nct_id": "NCT04034251",
      "title": "Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Gastric Cancer",
        "Esophagogastric Junction",
        "Peritoneal Carcinomatosis"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "BardPort Titanium Implanted Port with Peritoneal Catheter",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-06-09",
      "completion_date": "2024-09-05",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-06-11T09:24:24.407Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04034251"
    },
    {
      "nct_id": "NCT03921021",
      "title": "Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophagogastric Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Telomelysin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2019-05-09",
      "completion_date": "2023-07-20",
      "has_results": true,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-06-11T09:24:24.407Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03921021"
    },
    {
      "nct_id": "NCT06044311",
      "title": "Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma Esophagus",
        "Locally Advanced Adenocarcinoma",
        "Siewert Type I Adenocarcinoma of Esophagogastric Junction",
        "Siewert Type II Adenocarcinoma of Esophagogastric Junction"
      ],
      "interventions": [
        {
          "name": "Vactosertib",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Preoperative Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melissa Lumish",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-09-30",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-06-11T09:24:24.407Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06044311"
    }
  ]
}